A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure qualit

Trial Details

NCT ID

NCT07895498

Phase

PHASE2

Sponsor

Memorial Sloan Kettering Cancer Center

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Minocycline
Hypochlorous Acid
Hydrocortison cream
Triamcinolone (TAC) 0.1% cream
Clobetasol
Photoprotection

Locations (sample)

Basking Ridge, New Jersey, United States|40.70621,-74.54932
Middletown, New Jersey, United States|40.39428,-74.11709
Montvale, New Jersey, United States|41.04676,-74.02292
Commack, New York, United States|40.84288,-73.29289
Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
Female or male aged 18 years and older at the time of enrollment.
Not pregnant and not nursing.
No active infection requiring parenteral antibiotic(s).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →